(Boursier.com) — As expected, the turnover of Vetoquinol in the 3rd quarter amounted to 134 million euros (+1.4% on a reported basis and -4.5% at constant exchange rates). It reflects the expected landing of the post-Covid market and the negative effects of the geopolitical context, in particular in Europe and in food producing animals. Based on published data, Europe was down -8% in the 3rd quarter; the Americas and Asia/Pacific grew by +10% each.
Revenue for the first 9 months of the 2022 financial year amounted to €405 million, up +4.4% compared to the same period of the previous financial year and stable (-0.3%) at constant changes. It is in line with the outlook expected for the end of the financial year.
Since the start of the fiscal year, the laboratory has launched several Essentials that materialize Vetoquinol’s ambition: Felpreva, Imoxi and Phovia. The contribution to Group sales of these global brands will accelerate as they gain momentum.
As of September 30, the Vetoquinol laboratory displays a solid financial structure.
©2022 Boursier.com